Human Immunoglobulin for Intravenous Use I.P 10% Solution
₦488,000.00
Human Immunoglobulin (IVIG) is a blood product derived from pooled human plasma, containing a high concentration of immunoglobulin G (IgG) antibodies. This preparation is used to provide passive immunity and support the immune system in various clinical conditions.
Indications: IVIG is commonly prescribed for:
- Primary immunodeficiency disorders
- Secondary immunodeficiency due to underlying diseases
- Autoimmune disorders (e.g., Guillain-Barré syndrome, myasthenia gravis)
- Inflammatory conditions (e.g., Kawasaki disease)
- Certain infections and sepsis
Dosage:
- The dosage varies based on the specific indication and patient condition. It is typically administered intravenously.
- Common dosing may range from 0.4g to 2g per kilogram of body weight, depending on the clinical scenario and guidelines provided by a healthcare professional.
Key Features:
- Immunomodulatory Effects: Helps modulate the immune response, providing benefits in autoimmune and inflammatory diseases.
- Supports Immune Function: Provides immediate passive immunity in patients with immune deficiencies.
- High Concentration: The 10% solution allows for smaller volumes to be infused, which can be beneficial for patient comfort.
Side Effects: Possible side effects may include:
- Headache
- Fever
- Chills
- Nausea
- Allergic reactions (in rare cases)
- Risk of thromboembolic events
Precautions:
- Not recommended for individuals with a known allergy to human immunoglobulin products.
- Use with caution in patients with renal impairment or those at risk of thrombosis.
- Consult a healthcare professional before use if pregnant or breastfeeding.
Storage: Store in a cool, dry place, typically in a refrigerator (2°C to 8°C). Protect from light and do not freeze. Keep out of reach of children.
- Very secured payment methods
- Shipping will be calculated on checkout
- Please note that price may increase due to exchange rate, ensure updated price before making payment
Dispensing supervised byPharm. Tope Kareem, B.PharmPCN Reg. 023669
Last updated 28 August 2026How we write and check this informationPCN Premises Licence LAG20247B39C9




